Pfizer’s chief strategist talks about weight problems medicine, R&D and extra
NEW YORK — In his first public feedback, Pfizer’s new innovation chief — as soon as a Wall Avenue analyst skeptical of the corporate — stated he was assured within the firm’s weight problems plans and make clear why he joined the pharmaceutical big.
Andrew Baum was managing director of fairness analysis at Citigroup till final Could, when Pfizer introduced that he would tackle the function of chief technique and innovation officer. As such, Baum is concerned in promoting the corporate’s R&D plans to buyers — no small feat with an activist investor respiratory down the corporate’s neck and a fragile inventory value.
CEO Albert Bourla made a “pragmatic and considerate” evaluation of the corporate when he approached Baum in early 2024, Baum informed the group at STAT’s Breakthrough Summit East Thursday. Pfizer’s R&D crew has created efficient medicines, he assessed. They only haven’t executed so with income in thoughts.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
